BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma

NCT00117637 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

189

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Renal Cell

Interventions

DRUG: Sorafenib (Nexavar, BAY43-9006)
DRUG: Interferon

Sponsor

Bayer